NAMSA and Advanced Medical Solutions (AMS) have entered into a preferred partnership to accelerate the development and commercialization of AMS's product portfolio.
Under the agreement, AMS gains consolidated access to NAMSA's full suite of services, from regulatory, quality and biological safety consulting to biocompatibility, chemical characterization, microbiology and package integrity testing, through clinical research spanning study design, trial execution and post-market evidence generation. Bringing these services together under a single partner is designed to reduce handoffs between providers, improve continuity across development programs and shorten the path from design to market.
The partnership responds to rising demands on MedTech manufacturers for clinical and biological safety evidence, where more stringent expectations can extend development timelines, increase costs and delay patient access.
NAMSA CEO Brian Smith said the agreement reflects the strong foundation of trust, collaboration and shared purpose built over many years, and brings together AMS's innovation in tissue healing with NAMSA's expertise across preclinical testing, biological safety, regulatory strategy and clinical planning.
AMS said formalizing the preferred partnership is a natural evolution of the trust and collaborative success the teams have built, and that integrating NAMSA's preclinical and clinical expertise with its surgical and advanced wound care pipeline provides the expertise needed to clear regulatory hurdles and bring technologies to patients faster.
Founded in 1991 and headquartered in Winsford, UK, AMS designs and manufactures surgical and advanced wound care medical devices, including tissue adhesives, sutures, haemostats, internal fixation devices and sealants, sold in more than 100 countries under brands including LIQUIBAND, RESORBA, ActivHeal and Seal-G.